Takeda CEO: World must be 'more proactive' on outbreak prep by Eric Sagonowsky Thursday, February 20, 2020 The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.
Amgen-Astellas, Hengrui, coronavirus and more—FiercePharmaAsia by Angus Liu Friday, January 24, 2020 Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.
Inovio, Moderna score CEPI funding for coronavirus work by Eric Sagonowsky Thursday, January 23, 2020 CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.
CEPI, CureVac team up in $34M deal to advance RNA 'printer' by Eric Sagonowsky Wednesday, February 27, 2019 CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.
Sanofi, Dynavax and more—News of Note by Eric Sagonowsky Wednesday, January 16, 2019 Here is some other vaccine news of note for the week.
Emergent's new CEO, Valneva and more—News of Note by Angus Liu Wednesday, January 9, 2019 Here is some other vaccine news of note for the week.
Drone deliveries, HIV vaccines and more—News of Note by Eric Sagonowsky Wednesday, December 19, 2018 Here is some other vaccine news of note for the week.
Global coalition backs RNA vaccine platform to fight ‘Disease X’ by Angus Liu Monday, December 10, 2018 With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
Themis eyes phase 3 for chikungunya vaccine by Eric Sagonowsky Wednesday, November 7, 2018 There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.
Vaccines alliance hands J&J, Oxford $14.6M for MERS work by Eric Sagonowsky Thursday, September 27, 2018 In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.
